Tibet Aim Pharm. (002826)2025-01-22 10:35Financial Performance Projections - The estimated net profit attributable to shareholders for 2024 is projected to be between 35.65 million and 51.24 million yuan, representing a year-on-year growth of 131.70% to 233.02% compared to 15.39 million yuan in the previous year [2]. - The net profit after deducting non-recurring gains and losses is expected to be between 13.32 million and 19.14 million yuan, indicating a significant increase of 1,112.56% to 1,642.38% from 1.10 million yuan in the same period last year [2]. - Basic earnings per share are forecasted to be between 0.19 yuan and 0.28 yuan, up from 0.08 yuan per share in the previous year [2]. Factors Influencing Performance - The primary reason for the increase in performance is the absence of goodwill impairment losses, which were 19.80 million yuan in the previous year, resulting in a decrease in asset impairment losses [3]. - The company received 28.19 million yuan in industry support funds for 2023, which is an increase of 16.27 million yuan compared to the previous year, contributing to non-recurring gains [3].